• 1
    Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538-543.
  • 2
    Gonzalez-Porras J, Cordoba I, Such E, et al. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer. 2011;117:5529-5537.
  • 3
    Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705-1714.
  • 4
    Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351-1361.
  • 5
    Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of 6 cross-sectional physician surveys. J Natl Cancer Inst. 2008;100:1542-1551.
  • 6
    Manoharan A, Brighton T, Gemmell R, et al. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. Int J Hematol. 2002;76:272-278.
  • 7
    Mittelman M, Zeidman A. Platelet function in the myelodysplastic syndromes. Int J Hematol. 2000;71:95-98.
  • 8
    Andersen PK, Gill RD. Cox's Regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
  • 9
    Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672-1681.
  • 10
    Fenaux P, Kantarjian HM, Muus P, et al. Update of an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts). 2011;118. Abstract 2772.
  • 11
    Greenberg PL, Garcia-Manero G, Moore M, et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Leuk Lymphoma. 2012;54:321-328.
  • 12
    Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 250.
  • 13
    Kantarjian H, Giles F, Fenaux P, et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): preliminary results of a phase 1/2 study [abstract]. J Clin Oncol. 2007;25(18S). Abstract 7032.
  • 14
    Wang ES, Lyons RM, Larson RA, et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide [serial online]. J Hematol Oncol. 2012;5:71.
  • 15
    Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011;117:992-1000.
  • 16
    Heddle NM, Cook RJ, Webert KE, et al. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion. 2003;43:742-752.
  • 17
    Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia.Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto, N Engl J Med. 1997;337:1870-1875.
  • 18
    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-425.
  • 19
    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
  • 20
    Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.
  • 21
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
  • 22
    Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
  • 23
    Stasi R, Murali M, Michel M, et al. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. Int J Hematol. 2012;96:26-33.
  • 24
    Weitz I, Sanz MA, Henry D, et al. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28:789-796.
  • 25
    Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996;88:511-521.
  • 26
    Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood. 1996;87:1833-1844.
  • 27
    Ninos JM, Jefferies LC, Cogle CR, et al. The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells [abstract]. J Transl Med. 2006;4:9.
  • 28
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.